カテゴリ： GlobalData, アメリカ, 企業調査

Alexion Pharmaceuticals Inc (ALXN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Alexion Pharmaceuticals Inc (ALXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012284
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：137
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Alexion Pharmaceuticals Inc (Alexion) focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic diseases, cancer, neurological, and autoimmune disorders. The company’s marketed product portfolio includes Soliris (eculizumab) used for two indications paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS); Strensiq (asfotase alfa) for the treatment of hypophosphatasia (HPP)and Kanuma (sebelipase alfa) for the treatment of Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D). The company’s research and development focuses on developing its lead product Soliris, for various other serious disease states. It also has other candidates in development targeting rare metabolic and inflammatory disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc (ALXN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 12
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Alexion Acquires Patents Of An Investigational Therapy For Infants From Orphatec 15
Venture Financing 17
Moderna Therapeutics Raises USD450 Million in Venture Financing 17
Synageva Biopharma Secures US$25 Million In Equity Financing 19
Private Equity 20
TRC Capital To Acquire 0.77% Stake In Alexion Pharma For US$136 Million 20
Partnerships 21
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 21
X-Chem Enters into Discovery Agreement with Alexion Pharma 22
Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 23
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 25
Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 26
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 27
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 28
Merger 29
Synageva BioPharma Completes Merger With Trimeris 29
Licensing Agreements 31
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31
Xencor Enters into Licensing Agreement with Alexion Pharma 32
Equity Offering 34
Synageva BioPharma Prices Public Offering of Shares for USD283 Million 34
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 36
Synageva BioPharma Completes Public Offering Of Shares For US$211.5 Million 37
Synageva BioPharma Completes Public Offering Of Shares For US$179 Million 39
Synageva BioPharma Completes Public Offering Of Common Stock For US$118 Million 41
Synageva BioPharma Completes Public Offering Of Common Stock For US$115 Million 42
Synageva BioPharma Completes Public Offering Of Common Stock For US$90 Million 44
Acquisition 46
Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 46
Alexion Pharma Completes Acquisition Of Enobia Pharma 48
Alexion Pharma Acquires Taligen Therapeutics 50
Alexion Pharmaceuticals Inc – Key Competitors 52
Alexion Pharmaceuticals Inc – Key Employees 53
Alexion Pharmaceuticals Inc – Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Recent Developments 57
Strategy And Business Planning 57
Sep 12, 2017: Alexion Announces Restructuring to Advance Corporate Strategy 57
Financial Announcements 59
Jul 27, 2017: Alexion Reports Second Quarter 2017 Results 59
Apr 27, 2017: Alexion Reports First Quarter 2017 Results 60
Feb 16, 2017: Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017 61
Oct 27, 2016: Alexion Reports Third Quarter 2016 Results 63
Jul 28, 2016: Alexion Reports Second Quarter 2016 Results 65
Apr 28, 2016: Alexion Reports First Quarter 2016 Results 67
Feb 03, 2016: Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016 69
Corporate Communications 71
Nov 08, 2017: Alexion Appoints Francois Nader, M.D. to its Board of Directors 71
Sep 14, 2017: Alexion Adds Paul A. Friedman, M.D. to Its Board of Director 72
Jun 13, 2017: Alexion Names Paul Clancy Chief Financial Officer 73
Jun 01, 2017: Alexion Announces Additions To Executive Leadership Team 74
May 23, 2017: Alexion Announces Executive Leadership Changes 76
Mar 27, 2017: Alexion Appoints Ludwig Hantson, Ph.D., As Chief Executive Officer 78
Mar 24, 2017: Alexion submits application to Japan’s MHLW to extend Soliris indication to treat gMG 79
Mar 02, 2017: Leonard Bell, M.D., Alexion’s Founder, Announces Plans to Retire as Chairman and Board Member 80
Dec 13, 2016: Alexion Pharmaceuticals names David Brennan as interim CEO 82
Dec 12, 2016: Alexion Pharmaceuticals appoints interim CEO 84
Dec 12, 2016: Alexion’s Board Of Directors Announces New Leadership Appointments 86
Product News 88
12/21/2016: Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris) for the Prevention of Delayed Graft Function (DGF) After Kidney Transplantation 88
12/04/2016: New Data From ALXN1210 Dose-Escalation Study Presented At ASH Show Rapid And Sustained Reductions In LDH In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 89
11/17/2016: New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant 91
11/03/2016: Researchers to Present New Phase 1/2 Data on ALXN1210 in Patients with PNH at ASH 2016 Annual Meeting 93
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 94
07/14/2016: Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB) 96
07/06/2016: Federal Court Dismisses Challenge to Constitutionality of Federal Government’s Drug Price Watchdog 98
06/10/2016: Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH 99
03/03/2016: New Data Presented at WORLDSymposium 2016 Show Substantial Survival Benefit Beyond 2 Years of Age in Infants with Lysosomal Acid Lipase Deficiency Treated with Kanuma(sebelipase alfa) 100
03/03/2016: Ensemble Therapeutics Achieves Milestone 102
02/16/2016: A Statement from the Executive Officer of the Ontario Public Drug Programs on behalf of the pCPA 103
01/04/2017: Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016 104
Product Approvals 105
Mar 08, 2017: FDA Accepts sBLA Filing of Soliris (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis 105
Jan 06, 2017: FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria 106
Oct 19, 2016: FDA Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease 107
Sep 22, 2016: Alexion statement: NICE 2nd ECD for Strensiq (asfotase alfa) 108
Aug 29, 2016: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease 109
Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) 110
Mar 28, 2016: Kanuma (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency 111
Feb 18, 2016: NICE calls for more research into promising new drug to treat inherited rare enzyme deficiency 112
Clinical Trials 114
Mar 22, 2017: Alexion Submits Application In Japan For Soliris As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis 114
Jan 09, 2017: Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG) 115
Nov 11, 2016: New Long-Term Data Presented at AASLD Show Reduction in Liver Fibrosis and Cirrhosis in a Cohort of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma (sebelipase alfa) 116
Oct 27, 2016: Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) 118
Oct 06, 2016: New Long-Term Data Presented at WCPGHAN 2016 Show Rapid and Sustained Improvements in Important Markers of Liver Injury and Lipid Abnormalities in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma (sebelipase alfa) 120
Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress 122
Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association 124
Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) 125
May 19, 2016: Researchers to Present Additional Data, Including Late-Breaking Results on ALXN1007 in Patients with GI-GVHD at EHA Annual Congress 127
Apr 04, 2016: Data Presented at ENDO 2016 Show Sustained Improvements in Survival Rates, Bone Healing, Respiratory Support and Physical Function in Children with Hypophosphatasia (HPP) Receiving Long-Term Treatment with Strensiq (asfotase alfa) 128
Jan 15, 2016: Researchers to Present New Data at ENDO 2016 Advancing the Understanding of Strensiq (asfotase alfa) in Infants, Children and Adult Patients with Hypophosphatasia (HPP) 131
Other Significant Developments 132
Jul 27, 2017: Moderna Provides Update on mRNA Rare Disease R&D Strategy 132
Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 133
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 135
Jul 08, 2016: Alexion Announces €100 Million Investment in Athlone Site With Construction of New Manufacturing Facility 136
Appendix 137
Methodology 137
About GlobalData 137
Contact Us 137
Disclaimer 137

List of Tables
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Alexion Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 12
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Alexion Acquires Patents Of An Investigational Therapy For Infants From Orphatec 15
Moderna Therapeutics Raises USD450 Million in Venture Financing 17
Synageva Biopharma Secures US$25 Million In Equity Financing 19
TRC Capital To Acquire 0.77% Stake In Alexion Pharma For US$136 Million 20
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 21
X-Chem Enters into Discovery Agreement with Alexion Pharma 22
Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 23
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 25
Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 26
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 27
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 28
Synageva BioPharma Completes Merger With Trimeris 29
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31
Xencor Enters into Licensing Agreement with Alexion Pharma 32
Synageva BioPharma Prices Public Offering of Shares for USD283 Million 34
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 36
Synageva BioPharma Completes Public Offering Of Shares For US$211.5 Million 37
Synageva BioPharma Completes Public Offering Of Shares For US$179 Million 39
Synageva BioPharma Completes Public Offering Of Common Stock For US$118 Million 41
Synageva BioPharma Completes Public Offering Of Common Stock For US$115 Million 42
Synageva BioPharma Completes Public Offering Of Common Stock For US$90 Million 44
Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 46
Alexion Pharma Completes Acquisition Of Enobia Pharma 48
Alexion Pharma Acquires Taligen Therapeutics 50
Alexion Pharmaceuticals Inc, Key Competitors 52
Alexion Pharmaceuticals Inc, Key Employees 53
Alexion Pharmaceuticals Inc, Subsidiaries 54

★海外企業調査レポート[Alexion Pharmaceuticals Inc (ALXN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Shikoku Electric Power Co Inc (9507)：企業の財務・戦略的SWOT分析
    Shikoku Electric Power Co Inc (9507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • TBG Diagnostics Ltd (TDL)-医療機器分野：企業M&A・提携分析
    Summary TBG Diagnostics Ltd (TBG Diagnostics), formerly Progen Pharmaceuticals Ltd, is molecular diagnostics company that researches, develops, manufactures and markets molecular diagnostics kits, instruments and services. Its products are used in a wide range of applications such as medical researc …
  • Syngene International Ltd (SYNGENE)：企業の財務・戦略的SWOT分析
    Summary Syngene International Ltd (Syngene), a subsidiary of Biocon Ltd, is a clinical research and contract research and manufacturing organization. The organization offers research, development and manufacturing programs. It also provides discovery medicinal chemistry, small molecule development, …
  • UOB Private Banking：企業の戦略・SWOT・財務情報
    UOB Private Banking - Strategy, SWOT and Corporate Finance Report Summary UOB Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Pregis LLC.：企業の戦略・SWOT・財務情報
    Pregis LLC. - Strategy, SWOT and Corporate Finance Report Summary Pregis LLC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • One Lambda Inc-医療機器分野：企業M&A・提携分析
    Summary One Lambda Inc (One Lambda), a subsidiary of Thermo Fisher Scientific Inc is a medical device company that offers laboratory products. The company develops and distributes histocompatibility typing tests and antibody detection products. Its products include HLA tissue typing trays, HLA testi …
  • Cara Therapeutics Inc (CARA)-医療機器分野：企業M&A・提携分析
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a clinical-stage biotechnology company that develops novel therapeutics for pain and inflammation and pruritus. The company products include kappa receptor agonists and cannabinoid receptors. It offers products for therapeutic areas which include …
  • Electricity & Water Authority：企業の戦略的SWOT分析
    Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • U.S. Department of Health and Human Services-製薬・医療分野：企業M&A・提携分析
    Summary U.S. Department of Health and Human Services (HHS) is a healthcare service provider that offers patient care and support services. The organization’s service areas include health insurance marketplace, mental health, food safety, fighting HIV or AIDS, supporting military families, statistics …
  • Allegis Group, Inc.：企業の戦略的SWOT分析
    Allegis Group, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Firestone Diamonds plc：企業の戦略・SWOT・財務情報
    Firestone Diamonds plc - Strategy, SWOT and Corporate Finance Report Summary Firestone Diamonds plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Vivergo Fuels Ltd：企業の戦略的SWOT分析
    Vivergo Fuels Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • UniCredit S.p.A：企業のM&A・事業提携・投資動向
    UniCredit S.p.A - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UniCredit S.p.A Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Fraser & Neave Holdings Bhd：戦略・SWOT・企業財務分析
    Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Foshan Electrical and Lighting Co Ltd (000541)：企業の財務・戦略的SWOT分析
    Summary Foshan Electrical and Lighting Co Ltd (Foshan Lighting) is a manufacturer and marketer of lighting products and electrical equipment. The company's products include home lighting, LED lighting products, traditional lighting and fixtures, vehicle lighting products, and electrical supports. It …
  • Daxor Corp (DXR)：企業の財務・戦略的SWOT分析
    Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Stentys SA (STNT)：企業の財務・戦略的SWOT分析
    Summary Stentys SA (Stentys) is a medical device company that designs, develops and markets self-expanding stents for the treatment of patients with acute myocardial infarction and coronary disease. The company’s products include xposition S self-applying stent, mistent biodegradable sirolimus relea …
  • IES Holdings Inc (IESC)：企業の財務・戦略的SWOT分析
    IES Holdings Inc (IESC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • China Vanke Co., Ltd.：企業のM&A・事業提携・投資動向
    China Vanke Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Vanke Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • KFG Resources Ltd (KFG)：企業の財務・戦略的SWOT分析
    Summary KFG Resources Ltd (KFG) is a petroleum and natural gas exploration company that supplies natural gas. The company produces crude oil and natural gas through its reserves. Its oil and gas reserves are located in Mississippi, Wilcox, and Louisiana. KFG’s Mississippi’s projects comprise Carthag …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆